We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PLMR:NASDAQPalomar Holdings, Inc. Analysis

Data as of 2026-09-04 - not real-time

$136.58

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

At $136.58, Palomar Holdings, Inc. shows no decisive moving-average alignment, leaving the trend neutral. With RSI at 58.5 the momentum picture is neutral, alongside a bullish MACD signal. Price has been bracketed by support at $123.60 and resistance at $137.40.
On valuation the read is fair — earnings multiple of 18.4 versus a 16.5 sector average, above the peer group. Analyst price targets sit 19.5% above the current price. Revenue is growing at 54.7% on a 18.6% profit margin. The 1.32% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 5 — moderate. With 30-day volatility of 34.4%, a beta of -0.25 and a maximum drawdown of 26.1%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: buy, at a conviction of 6 out of 10.

Top Market Events

Palomar Holdings Inc PLMR delivers 15th consecutive earnings beat with 27% premium growth, while navigating intense...Specialty insurance provider Palomar Holdings NASDAQ:PLMR reported Q2 CY2026 results , with sales up 54.Palomar Holdings, Inc. Reports Second Quarter 2026 Results. LA JOLLA, Calif., Aug. 04, 2026 GLOBE NEWSWIRE -- Palomar...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 5/10

Key Factors

  • Trading above the 200-day average of 125.12
  • MACD momentum is positive
  • Maximum drawdown of 26.1%

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • P/E of 18.4 versus sector average of 16.5
  • Trading above the 200-day average of 125.12
  • Analyst targets imply +19.5% versus the current price

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • P/E of 18.4 versus sector average of 16.5
  • Analyst targets imply +19.5% versus the current price
  • Profit margin of 18.6% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth54.70%
Profit Margin18.62%
P/E Ratio18.4
ROE22.23%
ROA4.99%
Debt/Equity30.15
P/B Ratio3.6
Op. Cash Flow$415.3M
Free Cash Flow$569.9M
Industry P/E16.5

Technical Analysis

TrendNeutral
RSI58.5
Support$123.60
Resistance$137.40
MA 20$130.68
MA 50$133.91
MA 200$125.12
MACDBullish
VolumeDecreasing
Fear & Greed Index95.48

Valuation

Fair Value$733.21
Target Price$163.17
Upside/Downside19.47%
GradeFair
TypeBlend
Dividend Yield1.32%

Risk Assessment

Beta-0.25
Volatility34.41%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.